TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Genmab ( (GMAB) ) is now available.
On November 10, 2025, Genmab A/S announced a proposed private offering of $1.5 billion in senior secured notes due 2032 and $1.0 billion in senior unsecured notes due 2033, alongside the syndication of a new $2.0 billion senior secured term loan facility. The funds raised will be used to finance the acquisition of Merus N.V., a strategic move expected to enhance Genmab’s market position in the biotechnology sector. The offering is part of a broader financing strategy that includes previously syndicated credit facilities, and it underscores Genmab’s commitment to expanding its operational capabilities and market reach.
The most recent analyst rating on (GMAB) stock is a Buy with a $41.00 price target. To see the full list of analyst forecasts on Genmab stock, see the GMAB Stock Forecast page.
Spark’s Take on GMAB Stock
According to Spark, TipRanks’ AI Analyst, GMAB is a Outperform.
Genmab’s overall stock score reflects strong financial performance and positive earnings call sentiment, offset by bearish technical indicators. The company’s robust balance sheet and strategic growth initiatives are significant strengths, while recent revenue and cash flow declines pose challenges. The stock’s undervaluation presents a potential opportunity for investors.
To see Spark’s full report on GMAB stock, click here.
More about Genmab
Genmab A/S is a biotechnology company based in Denmark, specializing in the development of antibody therapeutics for the treatment of cancer. The company focuses on creating innovative and differentiated antibody products, leveraging its proprietary technologies such as DuoBody, HexaBody, and DuoHexaBody.
Average Trading Volume: 2,106,008
Technical Sentiment Signal: Buy
Current Market Cap: $17.9B
For an in-depth examination of GMAB stock, go to TipRanks’ Overview page.